MedTrace Logo

Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)

NCT00326339 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 189

Last updated 2009-04-20

No results posted yet for this study

Summary

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, ascending dose, dose ranging study to evaluate up to three doses of R935788 (50 mg bid, 100 mg bid and 150 mg bid). Approximately 180 patients who have had rheumatoid arthritis for a minimum of 12 months and who have been receiving a weekly methotrexate (MTX) dose for a minimum of 6 months will be enrolled into the study.

Conditions

Interventions

DRUG

R788

R788 50 mg, 100 mg, or 150 mg PO bid

DRUG

Placebo

Placebo PO bid

Sponsors & Collaborators

  • Rigel Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Elliott Grossbard, M.D. · Rigel Pharmaceuticals

  • Michael Weinblatt, M.D. · Brigham and Women's Hospital

  • Arthur Kavanaugh, M.D. · University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2007-10-31
Completion
2007-12-31

Countries

  • United States
  • Mexico

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00326339 on ClinicalTrials.gov